Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 236 articles:
HTML format
Text format



Single Articles


    March 2017
  1. MARTIN NK, Vickerman P, Hickman M
    How to eliminate HCV infection by antiviral treatment.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30142.
    PubMed     Text format    


  2. BRUNETTO M, Cornberg M, Chan HL
    How Good Is Hepatitis B Surface Antigen Kinetics Informing Strategy to Stop Antiviral Therapy?
    J Hepatol. 2017 Mar 15. pii: S0168-8278(17)30136.
    PubMed     Text format    


  3. MALLET V, Hamed K, Schwarzinger M
    Erratum to "Prognosis of patients with chronic hepatitis B in France (2008-2013): A nationwide, observational and hospital-based study".
    J Hepatol. 2017 Mar 8. pii: S0168-8278(17)30112.
    PubMed     Text format    


  4. BESTE LA, Green PK, Berry K, Kogut MJ, et al
    Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30126.
    PubMed     Text format     Abstract available


    February 2017
  5. PIROTH L, Wittkop L, Lacombe K, Rosenthal E, et al
    Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-coinfected patients - French ANRS CO13 HEPAVIH cohort.
    J Hepatol. 2017 Feb 21. pii: S0168-8278(17)30107.
    PubMed     Text format     Abstract available


  6. RAMOS-CASALS M, Zignego AL, Ferri C, Brito-Zeron P, et al
    Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.
    J Hepatol. 2017 Feb 17. pii: S0168-8278(17)30105.
    PubMed     Text format     Abstract available


  7. YAN Z, Zeng J, Yu Y, Xiang K, et al
    HBVcircle: a Novel Tool to Investigate Hepatitis B Virus Covalently Closed Circular DNA.
    J Hepatol. 2017 Feb 14. pii: S0168-8278(17)30072.
    PubMed     Text format     Abstract available


  8. OLIVIERO B, Mantovani S, Varchetta S, Mele D, et al
    Hepatitis C virus-Induced NK Cell Activation Causes Metzincin-Mediated CD16 Cleavage and Impaired Antibody-Dependent Cytotoxicity.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30069.
    PubMed     Text format     Abstract available


  9. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    PubMed     Text format     Abstract available


  10. ZENG QL, Xu GH, Zhang JY, Li W, et al
    Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30060.
    PubMed     Text format     Abstract available


  11. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Real-world treatment for chronic hepatitis C infection in Germany. Analyses from drug prescription data, 2010 - 2015.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30059.
    PubMed     Text format     Abstract available


  12. CALLEJA JL, Crespo J, Rincon D, Ruiz-Antoran B, et al
    Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real world cohort.
    J Hepatol. 2017 Feb 8. pii: S0168-8278(17)30063.
    PubMed     Text format     Abstract available


  13. GREBELY J, Swan T, Hickman M, Bruneau J, et al
    Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30054.
    PubMed     Text format    


  14. PAWLOTSKY JM
    Consistent advice for people who inject drugs in the 2016 EASL Recommendations on treatment of hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30055.
    PubMed     Text format    


  15. ATKINSON SR, Way MJ, McQuillin A, Morgan MY, et al
    Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30051.
    PubMed     Text format     Abstract available


  16. PRENNER S, VanWagner LB, Flamm SL, Salem R, et al
    Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy with Direct-Acting Antivirals.
    J Hepatol. 2017 Feb 1. pii: S0168-8278(17)30053.
    PubMed     Text format     Abstract available


    January 2017
  17. FARQUHAR MJ, Humphreys IS, Rudge SA, Wilson GK, et al
    Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    J Hepatol. 2017 Jan 23. pii: S0168-8278(17)30013.
    PubMed     Text format     Abstract available


  18. ZEUZEM S, Mizokami M, Pianko S, Mangia A, et al
    NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus: Prevalence and Effect on Treatment Outcome.
    J Hepatol. 2017 Jan 17. pii: S0168-8278(17)30011.
    PubMed     Text format     Abstract available


  19. FILLIOL A, Piquet-Pellorce C, Raguenes-Nicol C, Dion S, et al
    RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis.
    J Hepatol. 2017 Jan 11. pii: S0168-8278(17)30009.
    PubMed     Text format     Abstract available


  20. KLAG T, Dietz J, Werner CR, Schwarz JM, et al
    Hepatitis C "true" late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30006.
    PubMed     Text format    


    December 2016
  21. LEBOSSE F, Testoni B, Fresquet J, Facchetti F, et al
    Intrahepatic innate immune response pathways are down-regulated in untreated chronic hepatitis B.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30757.
    PubMed     Text format     Abstract available


  22. LANGHANS B, Dieter Nischalke H, Kramer B, Hausen A, et al
    Increased peripheral cd4+ regulatory t cells persist after successful direct-acting antiviral treatment of chronic hepatitis C.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30752.
    PubMed     Text format     Abstract available


  23. FERNANDEZ I, Munoz-Gomez R, Pascasio JM, Baliellas C, et al
    Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis c.
    J Hepatol. 2016 Dec 27. pii: S0168-8278(16)30753.
    PubMed     Text format     Abstract available


  24. VUKOTIC R, Conti F, Andreone P
    Hepatitis C virus eradication in elderly: The challenge worth a long-life elixir?
    J Hepatol. 2016 Dec 21. pii: S0168-8278(16)30745.
    PubMed     Text format    


  25. VERRIER ER, Schuster C, Baumert TF
    Advancing hepatitis B virus entry inhibitors.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30706.
    PubMed     Text format    


  26. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    PubMed     Text format     Abstract available


  27. NI Y, Urban S
    Stem cell-derived hepatocytes: a promising novel tool to study Hepatitis B Virus infection.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30704.
    PubMed     Text format    


  28. WYLES D, Dvory-Sobol H, Svarovskaia Doehle ES, Martin R, et al
    Post-Treatment Resistance Analysis of Hepatitis C Virus from Phase 2 and 3 Clinical Trials of Ledipasvir/ Sofosbuvir.
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30699.
    PubMed     Text format     Abstract available


    November 2016
  29. PISCHKE S, Hartl J, Pas SD, Lohse AW, et al
    Hepatitis E virus infection beyond the liver?
    J Hepatol. 2016 Nov 29. pii: S0168-8278(16)30692.
    PubMed     Text format     Abstract available


  30. ZIEMER M, Koukoulioti E, Beyer S, Simon JC, et al
    Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids.
    J Hepatol. 2016 Nov 28. pii: S0168-8278(16)30691.
    PubMed     Text format    


  31. NOTARPAOLO A, Layese R, Magistri P, Gambato M, et al
    Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    J Hepatol. 2016 Nov 26. pii: S0168-8278(16)30688.
    PubMed     Text format     Abstract available


  32. TOYODA H, Kumada T, Tada T, Shimada N, et al
    Efficacy and Tolerability of an IFN-free Regimen with DCV/ASV for Elderly Patients Infected with HCV Genotype 1B.
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30686.
    PubMed     Text format     Abstract available


  33. SHIMURA S, Watashi K, Fukano K, Peel M, et al
    Cyclosporin derivatives inhibit hepatitis B virus entry without interfering the NTCP transporter.
    J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30683.
    PubMed     Text format     Abstract available


  34. HELLARD M, Pedrana A, Scott N
    Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination?
    J Hepatol. 2016 Nov 21. pii: S0168-8278(16)30680.
    PubMed     Text format    


  35. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed     Text format    


  36. MALLET V, Hamed K, Schwarzinger M
    Prognosis of Patients with Chronic Hepatitis B in France (2008-2013): A Nationwide, Observational and Hospital-based Study.
    J Hepatol. 2016 Nov 5. pii: S0168-8278(16)30642.
    PubMed     Text format     Abstract available


  37. WANG J, Du M, Huang H, Chen R, et al
    Consistent loss of serum HBV RNA might predict the "para-functional cure" of chronic hepatitis B.
    J Hepatol. 2016 Nov 5. pii: S0168-8278(16)30645.
    PubMed     Text format    


  38. JANJUA NZ, Chong M, Kuo M, Woods R, et al
    Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    J Hepatol. 2016 Nov 3. pii: S0168-8278(16)30637.
    PubMed     Text format     Abstract available


  39. FALADE-NWULIA O, Sulkowski M
    The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection.
    J Hepatol. 2016 Nov 2. pii: S0168-8278(16)30636.
    PubMed     Text format    


    October 2016
  40. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    PubMed     Text format     Abstract available


  41. LEMOINE M, Thursz MR
    Field battle against hepatitis B infection and HCC in Africa.
    J Hepatol. 2016 Oct 19. pii: S0168-8278(16)30578.
    PubMed     Text format     Abstract available


  42. BEGUELIN C, Moradpour D, Sahli R, Suter-Riniker F, et al
    Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.
    J Hepatol. 2016 Oct 13. pii: S0168-8278(16)30569.
    PubMed     Text format     Abstract available


  43. XIA Y, Carpentier A, Cheng X, Block PD, et al
    Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions.
    J Hepatol. 2016 Oct 13. pii: S0168-8278(16)30572.
    PubMed     Text format     Abstract available


  44. DEUFFIC-BURBAN S, Boursier J, Leroy V, Yazdanpanah Y, et al
    Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
    J Hepatol. 2016 Oct 12. pii: S0168-8278(16)30568.
    PubMed     Text format     Abstract available


  45. ROSS DB, Belperio PS, Chartier M, Backus LI, et al
    Hepatitis C Testing in U.S. Veterans Born 1945-1965: An Update.
    J Hepatol. 2016 Oct 5. pii: S0168-8278(16)30557.
    PubMed     Text format    


  46. JUSTICE AC, Esserman D, Sarkar S, Levin FL, et al
    Reply to: "Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965".
    J Hepatol. 2016 Oct 4. pii: S0168-8278(16)30558.
    PubMed     Text format    


  47. VAN DER MEER AJ, Berenguer M
    Reversion of disease manifestations after HCV eradication.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  48. CACOUB P, Desbois AC, Isnard-Bagnis C, Rocatello D, et al
    Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  49. MAASOUMY B, Vermehren J
    Diagnostics in hepatitis C: The end of response-guided therapy?
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  50. EASTERBROOK PJ
    Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  51. MIDGARD H, Weir A, Palmateer N, Lo Re V 3rd, et al
    HCV epidemiology in high-risk groups and the risk of reinfection.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  52. HEIM MH, Bochud PY, George J
    Host - hepatitis C viral interactions: The role of genetics.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  53. BUKH J
    The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  54. MORADPOUR D, Grakoui A, Manns MP
    Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  55. YOUNOSSI ZM, Birerdinc A, Henry L
    Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences.
    J Hepatol. 2016;65.
    PubMed     Text format     Abstract available


  56. FORNS X, Berg T
    Hepatitis C virus - A teacher of clinical research, cell biology and immunology.
    J Hepatol. 2016;65.
    PubMed     Text format    


  57. VAN DER VALK M, Zaaijer HL, Kater AP, Schinkel J, et al
    Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.
    J Hepatol. 2016 Oct 1. pii: S0168-8278(16)30541.
    PubMed     Text format    


    September 2016
  58. CHAYANUPATKUL M, Omino R, Mittal S, Kramer JR, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2016 Sep 28. pii: S0168-8278(16)30540.
    PubMed     Text format     Abstract available


  59. INGILIZ P, Martin TC, Rodger A, Stellbrink HJ, et al
    HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.
    J Hepatol. 2016 Sep 17. pii: S0168-8278(16)30505.
    PubMed     Text format     Abstract available


  60. XIANG KH, Michailidis E, Ding H, Peng YQ, et al
    Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA.
    J Hepatol. 2016 Sep 17. pii: S0168-8278(16)30506.
    PubMed     Text format     Abstract available


  61. LAI CL, Wong D, Ip P, Kopaniszen M, et al
    Reduction of Covalently Closed Circular DNA with Long-term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B.
    J Hepatol. 2016 Sep 14. pii: S0168-8278(16)30487.
    PubMed     Text format     Abstract available



  62. EASL Recommendations on Treatment of Hepatitis C 2016.
    J Hepatol. 2016 Sep 12. pii: S0168-8278(16)30489.
    PubMed     Text format    


  63. POL S, Bourliere M, Lucier S, Hezode C, et al
    Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    J Hepatol. 2016 Sep 10. pii: S0168-8278(16)30486.
    PubMed     Text format     Abstract available


  64. WANG H, Tai AW
    Continuous de novo generation of spatially segregated hepatitis C virus replication organelles revealed by pulse-chase imaging.
    J Hepatol. 2016 Sep 3. pii: S0168-8278(16)30483.
    PubMed     Text format     Abstract available


  65. RIZZETTO M, Niro GA
    Myrcludex B, a novel therapy for chronic hepatitis D?
    J Hepatol. 2016;65:465-6.
    PubMed     Text format    


    August 2016
  66. ZAVAGLIA C, Okolicsanji S, Cesarini L, Mazzarelli C, et al
    Is the risk of neoplastic recurrence increased after prescribing Direct Acting Antivirals for HCV patients whose HCC was previously cured?
    J Hepatol. 2016 Aug 31. pii: S0168-8278(16)30481.
    PubMed     Text format    


  67. CORNBERG M, Wong VW, Locarnini S, Brunetto M, et al
    The role of quantitative hepatitis b surface antigen revisited.
    J Hepatol. 2016 Aug 26. pii: S0168-8278(16)30441.
    PubMed     Text format     Abstract available


  68. WAZIRY R, Grebely J, Amin J, Alavi M, et al
    Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).
    J Hepatol. 2016 Aug 25. pii: S0168-8278(16)30442.
    PubMed     Text format     Abstract available


  69. FUNG S, Kwan P, Fabri M, Horban A, et al
    Tenofovir disoproxil fumarate (TDF) versus TDF/emtricitabine (FTC) in lamivudine-resistant hepatitis B: a 5-year randomized study.
    J Hepatol. 2016 Aug 18. pii: S0168-8278(16)30440.
    PubMed     Text format     Abstract available


  70. INNES H, McDonald S, Hayes P, Dillon JF, et al
    Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.
    J Hepatol. 2016 Aug 18. pii: S0168-8278(16)30428.
    PubMed     Text format     Abstract available


  71. HEDEGAARD DL, Tully DC, Rowe IA, Reynolds GM, et al
    High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease.
    J Hepatol. 2016 Aug 13. pii: S0168-8278(16)30424.
    PubMed     Text format     Abstract available


  72. MINAMI T, Tateishi R, Nakagomi R, Fujiwara N, et al
    The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.
    J Hepatol. 2016 Aug 11. pii: S0168-8278(16)30419.
    PubMed     Text format    


  73. ROBAEYS G, Rob B, Azar DG, Razavi H, et al
    Global genotype distribution of hepatitis C viral infection among people who inject drugs.
    J Hepatol. 2016 Aug 9. pii: S0168-8278(16)30418.
    PubMed     Text format     Abstract available


  74. EBERHARD JM, Kummer S, Hartjen P, Hufner A, et al
    Reduced CD161+MAIT cell frequencies in HCV and HIV/HCV co-infection. Is the liver the heart of the matter?
    J Hepatol. 2016 Aug 1. pii: S0168-8278(16)30401.
    PubMed     Text format     Abstract available


    July 2016
  75. CARDOSO H, Vale AM, Rodrigues S, Goncalves R, et al
    High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30397.
    PubMed     Text format    


  76. ZENG QL, Li ZQ, Liang HX, Xu GH, et al
    Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30399.
    PubMed     Text format    


  77. VIONNET J, Saouli AC, Pascual M, Stucker F, et al
    Therapeutic Drug Monitoring for Sofosbuvir and Daclatasvir in Transplant Recipients with Chronic Hepatitis C and Advanced Renal Disease.
    J Hepatol. 2016 Jul 25. pii: S0168-8278(16)30347.
    PubMed     Text format    


  78. DEGASPERI E, De Nicola S, Rumi M, D'Ambrosio R, et al
    HCV-RNA Kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30344.
    PubMed     Text format    


  79. DESNOYER A, Le MP, Yazdanpanah Y, Peytavin G, et al
    Reply to: "Therapeutic Drug Monitoring for Sofosbuvir and Daclatasvir in Transplant Recipients with Chronic Hepatitis C and Advanced Renal Disease".
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30345.
    PubMed     Text format    


  80. MAASOUMY B, Vermehren J, Wedemeyer H, Sarrazin C, et al
    Clinical value of on-treatment HCV-RNA levels during treatment with sofosbuvir and ribavirin in genotype 3 patients.
    J Hepatol. 2016 Jul 23. pii: S0168-8278(16)30343.
    PubMed     Text format    


  81. YAMASHITA T, Nault JC
    Stemness of liver cancer: from hepatitis B virus to Wnt activation.
    J Hepatol. 2016 Jul 19. pii: S0168-8278(16)30338.
    PubMed     Text format    


  82. LI TC, Zhou X, Yoshizaki S, Ami Y, et al
    Production of Infectious Dromedary Camel Hepatitis E Virus by a Reverse Genetic System: Potential for Zoonotic Infection.
    J Hepatol. 2016 Jul 19. pii: S0168-8278(16)30337.
    PubMed     Text format     Abstract available



  83. Joint society statement for the elimination of viral hepatitis.
    J Hepatol. 2016 Jul 15. pii: S0168-8278(16)30339.
    PubMed     Text format    


  84. ALAVI M, Law MG, Grebely J, Amin J, et al
    Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012.
    J Hepatol. 2016 Jul 8. pii: S0168-8278(16)30321.
    PubMed     Text format     Abstract available


  85. YANG JD, Aqel BA, Pungpapong S, Gores GJ, et al
    Direct Acting Antiviral Therapy and Tumor Recurrence after Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.
    J Hepatol. 2016 Jul 5. pii: S0168-8278(16)30318.
    PubMed     Text format    


  86. CHEUNG MC, Walker AJ, Hudson BE, Verma S, et al
    Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30314.
    PubMed     Text format     Abstract available


    June 2016
  87. CONTI F, Buonfiglioli F, Scuteri A, Crespi C, et al
    Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals.
    J Hepatol. 2016 Jun 24. pii: S0168-8278(16)30303.
    PubMed     Text format     Abstract available


  88. FUNG J, Seto WK, Lai CL, Yuen J, et al
    Corrigendum to "Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy" [J Hepatol 2011;54:195-200].
    J Hepatol. 2016;64:1460.
    PubMed     Text format    


  89. COILLY A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, et al
    Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation - The CO23 ANRS CUPILT study.
    J Hepatol. 2016 Jun 1. pii: S0168-8278(16)30253.
    PubMed     Text format     Abstract available


    May 2016
  90. WANG J, Shen T, Huang X, Renuka Kumar G, et al
    Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.
    J Hepatol. 2016 May 28. pii: S0168-8278(16)30241.
    PubMed     Text format     Abstract available


  91. MANDORFER M, Kozbial K, Schwabl P, Freissmuth C, et al
    Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30238.
    PubMed     Text format     Abstract available


  92. MANI SK, Zhang H, Diab A, Pascuzzi PE, et al
    EpCAM-Regulated Intramembrane Proteolysis Induces a Cancer Stem Cell-like Gene Signature in Hepatitis B Virus-infected Hepatocytes.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30208.
    PubMed     Text format     Abstract available


  93. HARTL J, Denzer U, Ehlken H, Zenouzi R, et al
    Validation of transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30209.
    PubMed     Text format     Abstract available


  94. SUN J, Ma H, Xie Q, Xie Y, et al
    Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30210.
    PubMed     Text format     Abstract available


  95. TSENG A, Wong DK
    Hepatotoxicity and Potential Drug Interaction with Ledipasvir/Sofosbuvir In HIV/HCV Infected Patients.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30201.
    PubMed     Text format     Abstract available


  96. LOK AS, Pan CQ, Han SB, Trinh HN, et al
    Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.
    J Hepatol. 2016 May 19. pii: S0168-8278(16)30202.
    PubMed     Text format     Abstract available


  97. VANDENBULCKE H, Moreno C, Colle I, Knebel JF, et al
    Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis: a prospective study.
    J Hepatol. 2016 May 12. pii: S0168-8278(16)30184.
    PubMed     Text format     Abstract available


  98. DEBING Y, Ramiere C, Dallmeier K, Piorkowski G, et al
    Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity.
    J Hepatol. 2016 May 9. pii: S0168-8278(16)30187.
    PubMed     Text format     Abstract available


  99. BULTEEL N, Sarathy PP, Forrest E, Stanley AJ, et al
    Factors Associated with Spontaneous Clearance of Chronic Hepatitis c Virus Infection: a Retrospective Case Control Study.
    J Hepatol. 2016 May 4. pii: S0168-8278(16)30182.
    PubMed     Text format     Abstract available


  100. MOENNE-LOCCOZ R, Severac F, Baumert TF, Habersetzer F, et al
    Usefulness of corticosteroids as first-line therapy in patients with acute severe autoimmune hepatitis.
    J Hepatol. 2016 May 4. pii: S0168-8278(16)30183.
    PubMed     Text format    


  101. COLOMBO M
    EASL Recognition Award Recipient 2016: Prof. Antonio Craxi.
    J Hepatol. 2016;64:1001-2.
    PubMed     Text format    


  102. PADEGIMAS A, Forde KA, Goldberg LR, Birati EY, et al
    Myo-pericarditis secondary to ledipasvir-sofosbuvir therapy.
    J Hepatol. 2016;64:1196-8.
    PubMed     Text format    


    April 2016
  103. BLANK A, Markert C, Hohmann N, Carls A, et al
    Myrcludex B: a first-in-human clinical study with a first-in-class hepatitis B and hepatitis D virus entry inhibitor.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30145.
    PubMed     Text format     Abstract available


  104. BOGOMOLOV P, Alexandrov A, Voronkova N, Macievich M, et al
    Interim results of a Phase Ib/IIa study of the entry inhibitor myrcludex B in chronic hepatitis D infected patients.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30148.
    PubMed     Text format     Abstract available


  105. FOSTER G
    Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme".
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30142.
    PubMed     Text format    


  106. GRAY E, O'Leary A, Stewart S, Bergin C, et al
    High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30143.
    PubMed     Text format    


  107. SARKAR S, Esserman DA, Skanderson M, Levin FL, et al
    Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965.
    J Hepatol. 2016 Apr 26. pii: S0168-8278(16)30144.
    PubMed     Text format     Abstract available


  108. MAASOUMY B, Vermehren J, Welker MW, Bremer B, et al
    Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens.
    J Hepatol. 2016 Apr 13. pii: S0168-8278(16)30108.
    PubMed     Text format     Abstract available


  109. REIG M, Marino Z, Perello C, Inarrairaegui M, et al
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution.
    J Hepatol. 2016 Apr 12. pii: S0168-8278(16)30113.
    PubMed     Text format     Abstract available


  110. BHAMIDIMARRI KR, Martin P
    Finally safe and effective treatment options for hepatitis C in hemodialysis patients.
    J Hepatol. 2016 Apr 9. pii: S0168-8278(16)30105.
    PubMed     Text format    


  111. LUNEMANN S, Martrus G, Holzemer A, Chapel A, et al
    Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C03:04 and modulate NK cell function.
    J Hepatol. 2016 Apr 4. pii: S0168-8278(16)30097.
    PubMed     Text format     Abstract available


  112. MEHTA SH, Thomas DL
    Doing the math on hepatitis C virus treatment.
    J Hepatol. 2016 Apr 2. pii: S0168-8278(16)30096.
    PubMed     Text format    


  113. BLONDOT ML, Bruss V, Kann M
    Intracellular transport and egress of hepatitis B virus.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  114. LUCIFORA J, Protzer U
    Attacking hepatitis B virus cccDNA - The holy grail to hepatitis B cure.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  115. TONG S, Revill P
    Overview of hepatitis B viral replication and genetic variability.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  116. LI W, Urban S
    Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  117. ALLWEISS L, Dandri M
    Experimental in vitro and in vivo models for the study of human hepatitis B virus infection.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  118. DURANTEL D, Zoulim F
    New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  119. SUREAU C, Negro F
    The hepatitis delta virus: Replication and pathogenesis.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  120. DUBUQUOY L
    Lipocalin 2 highlights the complex role of neutrophils in alcoholic liver disease.
    J Hepatol. 2016;64:770-2.
    PubMed     Text format    


  121. LEVRERO M, Zucman-Rossi J
    Mechanisms of HBV-induced hepatocellular carcinoma.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  122. BERTOLETTI A, Ferrari C
    Adaptive immunity in HBV infection.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  123. MAINI MK, Gehring AJ
    The role of innate immunity in the immunopathology and treatment of HBV infection.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  124. SEEGER C, Mason WS
    HBV replication, pathobiology and therapy: Unanswered questions.
    J Hepatol. 2016;64.
    PubMed     Text format     Abstract available


  125. ROBERT O, Boujedidi H, Bigorgne A, Ferrere G, et al
    Decreased expression of the glucocorticoid receptor-GILZ pathway in Kupffer cells promotes liver inflammation in obese mice.
    J Hepatol. 2016;64:916-24.
    PubMed     Text format     Abstract available


    March 2016
  126. BRUNO S, Di Marco V, Iavarone M, Roffi L, et al
    Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
    J Hepatol. 2016 Mar 23. pii: S0168-8278(16)00075.
    PubMed     Text format     Abstract available


  127. DEBING Y, Moradpour D, Neyts J, Gouttenoire J, et al
    Update on Hepatitis E Virology:Implications for Clinical Practice.
    J Hepatol. 2016 Mar 7. pii: S0168-8278(16)30011.
    PubMed     Text format     Abstract available


  128. YOUNOSSI ZM, Stepanova M, Feld J, Zeuzem S, et al
    Sofosbuvir/Velpatasvir Improves Patient-Reported Outcomes in HCV Patients: Results from ASTRAL-1 Placebo-Controlled Trial.
    J Hepatol. 2016 Mar 5. pii: S0168-8278(16)30008.
    PubMed     Text format     Abstract available


  129. DESNOYER A, Pospai D, Le MP, Gervais A, et al
    Sofosbuvir-containing regimen for HCV infection in hemodialysis patients: 400 mg daily or only on the day of hemodialysis.
    J Hepatol. 2016 Mar 4. pii: S0168-8278(16)30010.
    PubMed     Text format     Abstract available


  130. YAMAMOTO N, Sato Y, Munakata T, Kakuni M, et al
    Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection.
    J Hepatol. 2016;64:547-55.
    PubMed     Text format     Abstract available


    February 2016
  131. VO M, Holz LE, Wong YC, English K, et al
    The extent and duration of acute hepatitis in mice is dominated by the function rather than by the survival of effector CD8 T cells.
    J Hepatol. 2016 Feb 25. pii: S0168-8278(16)00160.
    PubMed     Text format     Abstract available


  132. JACKA B, Applegate T, Poon AF, Raghwani J, et al
    Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.
    J Hepatol. 2016 Feb 25. pii: S0168-8278(16)00165.
    PubMed     Text format     Abstract available


  133. ZAHND C, Salazar-Vizcaya L, Dufour JF, Mullhaupt B, et al
    Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men.
    J Hepatol. 2016 Feb 24. pii: S0168-8278(16)00164.
    PubMed     Text format     Abstract available


  134. MOSTAFA A, Shimakawa Y, Medhat A, Mikhail NN, et al
    Excess mortality rate associated with hepatitis C virus infection: a community-based cohort study in rural Egypt.
    J Hepatol. 2016 Feb 24. pii: S0168-8278(16)00167.
    PubMed     Text format     Abstract available


  135. OZASLAN E, Efe C
    Further considerations in autoimmune hepatitis.
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00154.
    PubMed     Text format    


  136. LOHSE AW, Chazouilleres O, Dalekos G, Drenth J, et al
    Clinical Practise Guidelines Autoimmune Hepatitis: Further considerations.
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00159.
    PubMed     Text format    


  137. DAHARI H, Canini L, Graw F, Uprichard SL, et al
    HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
    J Hepatol. 2016 Feb 20. pii: S0168-8278(16)00153.
    PubMed     Text format     Abstract available


  138. GOUTTENOIRE J, Moradpour D
    A Mouse Model for Hepatitis E Virus Infection.
    J Hepatol. 2016 Feb 15. pii: S0168-8278(16)00122.
    PubMed     Text format    


  139. STEVEN FOX D, McCombs JS
    Optimizing HCV Treatment - Moving Beyond the Cost Conundrum.
    J Hepatol. 2016 Feb 11. pii: S0168-8278(16)00089.
    PubMed     Text format    


  140. GENG Y, Zhao C, Wang Y
    Reply to "Rhesus macaques persistently infected with hepatitis E shed virus into urine".
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00085.
    PubMed     Text format    


  141. MARTIN NK, Vickerman P, Dore GJ, Grebely J, et al
    How should HCV treatment be prioritized in the direct-acting antiviral era? An economic evaluation including population prevention benefits.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00086.
    PubMed     Text format     Abstract available


  142. HUANG F, Yang C, Zhou X, Yu W, et al
    Rhesus macaques persistently infected with hepatitis E shed virus into urine.
    J Hepatol. 2016 Feb 8. pii: S0168-8278(16)00082.
    PubMed     Text format    


  143. ESLAM M, Hashem AM, Romero-Gomez M, Berg T, et al
    FibroGENE: A gene-based model for staging liver fibrosis.
    J Hepatol. 2016;64:390-8.
    PubMed     Text format     Abstract available


  144. PAVLIDES M, Banerjee R, Sellwood J, Kelly CJ, et al
    Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.
    J Hepatol. 2016;64:308-15.
    PubMed     Text format     Abstract available


    January 2016
  145. FOSTER GR, Irving WL, Cheung MC, Walker AJ, et al
    Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jan 29. pii: S0168-8278(16)00065.
    PubMed     Text format     Abstract available


  146. WEBB G, Chen YY, Li KK, Neil D, et al
    Single-gene association between GATA-2 and autoimmune hepatitis: a novel genetic insight highlighting immunologic pathways to disease.
    J Hepatol. 2016 Jan 23. pii: S0168-8278(16)00051.
    PubMed     Text format     Abstract available


  147. UDOMPAP P, Mannalithara A, Heo N, Kim D, et al
    Increasing Prevalence of Cirrhosis among US Adults Aware or Unaware of their Chronic Hepatitis C Virus Infection.
    J Hepatol. 2016 Jan 22. pii: S0168-8278(16)00014.
    PubMed     Text format     Abstract available


  148. ALLWEISS L, Gass S, Giersch K, Groth A, et al
    Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation.
    J Hepatol. 2016 Jan 21. pii: S0168-8278(16)00017.
    PubMed     Text format     Abstract available


  149. YANG YH, Chen WC, Tsai YH, Chen PC, et al
    Reply to "Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection".
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00011.
    PubMed     Text format    


  150. HOOFNAGLE JH
    Hepatic Decompensation during Direct-Acting Antiviral Therapy of Chronic Hepatitis C.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00010.
    PubMed     Text format    


  151. YU ML
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00012.
    PubMed     Text format    


  152. MIDGARD H, Bjoro B, Maeland A, Konopski Z, et al
    Hepatitis C Reinfection Following Sustained Virological Response - Seven-Year Follow-Up Of Patients Infected Through Injecting Drug Use.
    J Hepatol. 2016 Jan 9. pii: S0168-8278(16)00003.
    PubMed     Text format     Abstract available


  153. BAUMERT TF, Schuster C, Cosset FL, Dubuisson J, et al
    Addressing the Next Challenges: a Summary of the 22nd International Symposium on Hepatitis C Virus and Related Viruses.
    J Hepatol. 2016 Jan 9. pii: S0168-8278(16)00004.
    PubMed     Text format     Abstract available


  154. YOUNOSSI ZM, Stepanova M, Estep M, Negro F, et al
    Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    J Hepatol. 2016;64:29-36.
    PubMed     Text format     Abstract available


    December 2015
  155. CHAN HL, Ahn SH, Chang TT, Peng CY, et al
    Peginterferon Lambda for the Treatment of HBeAg-Positive Chronic Hepatitis B: A Randomized Phase 2b Study (LIRA-B).
    J Hepatol. 2015 Dec 28. pii: S0168-8278(15)00859.
    PubMed     Text format     Abstract available


  156. HULLEGIE SJ, Claassen MA, van den Berk GE, van der Meer JT, et al
    A 12-Week Treatment with Boceprevir, Peginterferon and Ribavirin for Acute Hepatitis C in HIV infected patients.
    J Hepatol. 2015 Dec 12. pii: S0168-8278(15)00805.
    PubMed     Text format     Abstract available


  157. MARCHAN-LOPEZ A, Dominguez-Dominguez L, Kessler-Saiz P, Jarrin-Estupinan ME, et al
    Liver Failure in Human Immunodeficiency Virus - Hepatitis C Virus Coinfection Treated with Sofosbuvir, Ledipasvir and Antiretroviral Therapy.
    J Hepatol. 2015 Dec 9. pii: S0168-8278(15)00799.
    PubMed     Text format    


  158. DYSON JK, McPherson S
    Reply to "Liver Failure in Human Immunodeficiency Virus - Hepatitis C Virus Coinfection Treated with Sofosbuvir, Ledipasvir and Antiretroviral Therapy".
    J Hepatol. 2015 Dec 9. pii: S0168-8278(15)00800.
    PubMed     Text format    


  159. PAPATHEODORIDIS G, Dalekos G, Sypsa V, Yurdaydin C, et al
    Page-B: Risk Score for Hepatocellular Carcinoma in Caucasians with Chronic Hepatitis B Under 5-Year Entecavir or Tenofovir Therapy.
    J Hepatol. 2015 Dec 8. pii: S0168-8278(15)00795.
    PubMed     Text format     Abstract available


    November 2015
  160. WELKER MW, Luhne S, Lange CM, Vermehren J, et al
    Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00792.
    PubMed     Text format     Abstract available


  161. BILLIOUD G, Kruse RL, Carrillo M, Whitten-Bauer C, et al
    In vivo Reduction of Hepatitis B Virus Antigenemia and Viremia by Antisense Oligonucleotides.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00790.
    PubMed     Text format     Abstract available


  162. RAY KIM W, Berg T, Asselah T, Flisiak R, et al
    Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00770.
    PubMed     Text format     Abstract available


  163. HELSEN N, Debing Y, Paeshuyse J, Dallmeier K, et al
    Stem cell-derived hepatocytes: a novel model for hepatitis E virus replication.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00771.
    PubMed     Text format     Abstract available


  164. LEMPP FA, Mutz P, Lipps C, Wirth D, et al
    Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor.
    J Hepatol. 2015 Nov 11. pii: S0168-8278(15)00736.
    PubMed     Text format     Abstract available


  165. SHIELS MS, Robbins HA, Engels EA
    Letter to the editor on "Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010".
    J Hepatol. 2015 Nov 7. pii: S0168-8278(15)00726.
    PubMed     Text format    


  166. ALLISON RD, Holmberg SD
    Response to comment on "Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010".
    J Hepatol. 2015 Nov 7. pii: S0168-8278(15)00729.
    PubMed     Text format    


    October 2015
  167. DE NIET A, Stelma F, Jansen L, Sinnige MJ, et al
    Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy.
    J Hepatol. 2015 Oct 23. pii: S0168-8278(15)00712.
    PubMed     Text format     Abstract available


  168. FELD JJ, Moreno C, Trinh R, Tam E, et al
    Sustained Virologic Response of 100% in HCV Genotype 1b Patients with Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir for 12 Weeks.
    J Hepatol. 2015 Oct 14. pii: S0168-8278(15)00676.
    PubMed     Text format     Abstract available


  169. ZEUZEM S, Hezode C, Bronowicki JP, Loustaud-Ratti V, et al
    Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
    J Hepatol. 2015 Oct 7. pii: S0168-8278(15)00672.
    PubMed     Text format     Abstract available


  170. LEROY V, Asselah T
    Universal hepatitis B vaccination: the only way to eliminate hepatocellular carcinoma?
    J Hepatol. 2015 Oct 5. pii: S0168-8278(15)00667.
    PubMed     Text format    


    September 2015
  171. SARRAZIN C
    The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
    J Hepatol. 2015 Sep 24. pii: S0168-8278(15)00629.
    PubMed     Text format     Abstract available


  172. HEZODE C, Bronowicki JP
    Ideal oral combinations to eradicate HCV. The role of ribavirin.
    J Hepatol. 2015 Sep 24. pii: S0168-8278(15)00627.
    PubMed     Text format     Abstract available


  173. LIANG HW, Wang N, Wang Y, Wang F, et al
    Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via sequestering cellular microRNA-122.
    J Hepatol. 2015 Sep 23. pii: S0168-8278(15)00631.
    PubMed     Text format     Abstract available


  174. PARK YK, Park ES, Kim DH, Ahn SH, et al
    Cleaved c-FLIP mediates the antiviral effect of TNF-alpha against hepatitis B virus by dysregulating hepatocyte nuclear factors.
    J Hepatol. 2015 Sep 23. pii: S0168-8278(15)00630.
    PubMed     Text format     Abstract available


  175. YAN M, Ha J, Aguilar M, Bhuket T, et al
    Birth Cohort-Specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis, Treatment, and Long-term Survival.
    J Hepatol. 2015 Sep 16. pii: S0168-8278(15)00623.
    PubMed     Text format     Abstract available


  176. COILLY A, Samuel D
    Pros and Cons: Usage of organs from donors infected with hepatitis C virus - revision in the direct acting antiviral era.
    J Hepatol. 2015 Sep 12. pii: S0168-8278(15)00617.
    PubMed     Text format     Abstract available


  177. GERBER L, Younossi Z
    Fatigue in Patients with Chronic Hepatitis C.
    J Hepatol. 2015 Sep 12. pii: S0168-8278(15)00616.
    PubMed     Text format    


  178. PAWLOTSKY JM, Aghemo A, Back D, Dusheiko G, et al
    Should HCV-infected patients with debilitating fatigue be prioritized for treatment with interferon-free regimens?
    J Hepatol. 2015 Sep 12. pii: S0168-8278(15)00619.
    PubMed     Text format    


  179. GENG Y, Zhao C, Huang W, Harrison TJ, et al
    Detection and assessment of infectivity of hepatitis E virus in urine.
    J Hepatol. 2015 Sep 8. pii: S0168-8278(15)00615.
    PubMed     Text format     Abstract available


  180. KHATRI A, Menon R
    Reply to comments on: Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Sep 5. pii: S0168-8278(15)00612.
    PubMed     Text format    


  181. CHTIOUI H, Buclin T
    Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Sep 4. pii: S0168-8278(15)00610.
    PubMed     Text format    


    August 2015
  182. DORE GJ, Conway B, Luo Y, Janczewska E, et al
    Randomized trials of ombitasvir/paritaprevir/r+dasabuvir+/-ribavirin vs telaprevir+pegIFN/ribavirin in adults with genotype 1 HCV.
    J Hepatol. 2015 Aug 27. pii: S0168-8278(15)00557.
    PubMed     Text format     Abstract available


  183. WOLTER F, Glassner A, Kramer B, Kokordelis P, et al
    Hypoxia impairs anti-viral activity of natural killer (NK) cells but has little effect on anti-fibrotic NK cell functions in hepatitis C virus infection.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00550.
    PubMed     Text format     Abstract available


  184. GRANCINI V, Trombetta M, Lunati ME, Zimbalatti D, et al
    Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00553.
    PubMed     Text format     Abstract available


  185. BRUNO R, Aghemo A
    Hepatitis C Virus Post-exposure prophylaxis: a reasonable option in the era of pangenotypic directly acting antivirals?
    J Hepatol. 2015 Aug 18. pii: S0168-8278(15)00549.
    PubMed     Text format    



  186. EASL Clinical Practice Guidelines: Autoimmune hepatitis.
    J Hepatol. 2015 Aug 13. pii: S0168-8278(15)00458.
    PubMed     Text format    


  187. HJERRILD S, Dalgard O, Christensen PB, Leutscher P, et al
    Debilitating fatigue as a treatment indication in chronic hepatitis C.
    J Hepatol. 2015 Aug 8. pii: S0168-8278(15)00540.
    PubMed     Text format    


  188. HUNG GY, Horng JL, Yen HJ, Lee CY, et al
    Changing Incidence Patterns of Hepatocellular Carcinoma Among Age Groups in Taiwan.
    J Hepatol. 2015 Aug 6. pii: S0168-8278(15)00534.
    PubMed     Text format     Abstract available


  189. GREBELY J, Haire B, Taylor LE, Macneill P, et al
    Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data?
    J Hepatol. 2015 Aug 4. pii: S0168-8278(15)00406.
    PubMed     Text format    


    July 2015
  190. EL-SHAMY A, Eng FJ, Doyle EH, Klepper AL, et al
    A Cell Culture System for Distinguishing Hepatitis C Viruses with and without Liver Cancer-related Mutations in the Viral Core Gene.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00515.
    PubMed     Text format     Abstract available


  191. LUANGSAY S, Gruffaz M, Isorce N, Testoni B, et al
    Early Inhibition of Hepatocyte Innate Responses by Hepatitis B Virus.
    J Hepatol. 2015 Jul 24. pii: S0168-8278(15)00477.
    PubMed     Text format     Abstract available


  192. HSIANG JC, Wong GL, Tse YK, Wong VW, et al
    Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity-score landmark analysis.
    J Hepatol. 2015 Jul 21. pii: S0168-8278(15)00472.
    PubMed     Text format     Abstract available


  193. YANG YH, Chen WC, Tsan YT, Chen MJ, et al
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2015 Jul 18. pii: S0168-8278(15)00469.
    PubMed     Text format     Abstract available


  194. O'BRIEN TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, et al
    Comparison of Functional Variants in IFNL4 and IFNL3 for Association with Hepatitis C Virus Clearance.
    J Hepatol. 2015 Jul 14. pii: S0168-8278(15)00465.
    PubMed     Text format     Abstract available


  195. ARENDS JE, Lieveld F, Boeijen LL, de Kanter CT, et al
    Natural history and treatment of Hepatitis C/HIV coinfection: is it time to change paradigms?
    J Hepatol. 2015 Jul 14. pii: S0168-8278(15)00462.
    PubMed     Text format     Abstract available


  196. YEOMAN AD, Kotha S, Heneghan MA
    Reply to "The role of corticosteroids in acute-severe autoimmune hepatitis is still highly debatable".
    J Hepatol. 2015 Jul 8. pii: S0168-8278(15)00457.
    PubMed     Text format    


  197. LAMPERTICO P, Maini M, Papatheodoridis G
    Optimal Management of Hepatitis B Virus Infection - EASL Special Conference.
    J Hepatol. 2015 Jul 3. pii: S0168-8278(15)00453.
    PubMed     Text format     Abstract available


  198. CHAN HL, Elkhashab M, Trinh H, Tak WY, et al
    Association of Baseline Vitamin D Levels With Clinical Parameters and Treatment Outcomes in Chronic Hepatitis B.
    J Hepatol. 2015 Jul 1. pii: S0168-8278(15)00452.
    PubMed     Text format     Abstract available


  199. RIVIERE L, Gerossier L, Ducroux A, Dion S, et al
    HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase.
    J Hepatol. 2015 Jul 1. pii: S0168-8278(15)00450.
    PubMed     Text format     Abstract available


    June 2015
  200. SONG ZZ
    Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
    J Hepatol. 2015 Jun 30. pii: S0168-8278(15)00416.
    PubMed     Text format    


  201. DE MARTIN E, Coilly A, Ichai P, Samuel D, et al
    The role of corticosteroids in acute-severe autoimmune hepatitis is still highly debatable.
    J Hepatol. 2015 Jun 30. pii: S0168-8278(15)00417.
    PubMed     Text format    


  202. FERENCI P, Kozbial K, Mandorfer M, Hofer H, et al
    HCV targeting of patients with cirrhosis.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00393.
    PubMed     Text format     Abstract available


  203. LAMPERTICO P, Invernizzi F, Vigano M, Loglio A, et al
    The long-term benefits of nucleos(t)ide analogs on esophageal varices in compensated HBV cirrhotics with no or small esophageal varices: A 12-year prospective cohort study.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00397.
    PubMed     Text format     Abstract available


  204. BHAMIDIMARRI K, Czul F, Peyton A, Levy C, et al
    Safety, efficacy and tolerability of Simeprevir plus half-dose Sofosbuvir in treatment of Hepatitis C in patients with end stage renal disease.
    J Hepatol. 2015 Jun 18. pii: S0168-8278(15)00394.
    PubMed     Text format    


  205. ALMISHRI W, Deans J, Swain MG
    Rapid activation and hepatic recruitment of innate-like regulatory B cells after invariant NKT cell stimulation in mice.
    J Hepatol. 2015 Jun 18. pii: S0168-8278(15)00398.
    PubMed     Text format     Abstract available


  206. KHATRI A, Menon R, Marbury TC, Lawitz E, et al
    Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
    J Hepatol. 2015 Jun 10. pii: S0168-8278(15)00387.
    PubMed     Text format     Abstract available


  207. KOUTSOUDAKIS G, Romero-Brey I, Berger C, Perez-Vilaro G, et al
    Soraphen A: a broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.
    J Hepatol. 2015 Jun 9. pii: S0168-8278(15)00391.
    PubMed     Text format     Abstract available


  208. WU C, Dunn W
    Is it worthy of switching to PegIFN alfa-2a in patients achieving virological suppression with entecavir?
    J Hepatol. 2015;62:1439-40.
    PubMed     Text format    


    May 2015
  209. WONG VW, Janssen HL
    Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?
    J Hepatol. 2015 May 27. pii: S0168-8278(15)00346.
    PubMed     Text format     Abstract available


  210. RICARDO-LAX I, Ramanan V, Michailidis E, Shamia T, et al
    Hepatitis B virus induces RNR-R2 expression via DNA damage response activation.
    J Hepatol. 2015 May 27. pii: S0168-8278(15)00344.
    PubMed     Text format     Abstract available


  211. SELVAPATT N, Ward T, Bailey H, Bennett H, et al
    Is antenatal screening for hepatitis C virus cost effective? A decade's experience at a London centre.
    J Hepatol. 2015 May 26. pii: S0168-8278(15)00342.
    PubMed     Text format     Abstract available


  212. MEHTA G, Dusheiko G
    Hepatitis C treatment and quality of life - you can't always get what you want, but you might get what you need.
    J Hepatol. 2015 May 13. pii: S0168-8278(15)00326.
    PubMed     Text format    


  213. KUSHNER T, Serper M, Kaplan DE
    Delta Hepatitis within the Veterans Affairs Medical System in the United States: Prevalence, Risk Factors, and Outcomes.
    J Hepatol. 2015 May 8. pii: S0168-8278(15)00319.
    PubMed     Text format     Abstract available


  214. SHARMA S, Carballo M, Feld JJ, Janssen HL, et al
    Immigration and Viral Hepatitis.
    J Hepatol. 2015 May 8. pii: S0168-8278(15)00320.
    PubMed     Text format     Abstract available


    April 2015
  215. PAWLIK TM, Soubrane O
    Metabolic syndrome-associated hepatocellular carcinoma: questions still unanswered.
    J Hepatol. 2015 Apr 7. pii: S0168-8278(15)00245.
    PubMed     Text format    


  216. PEIFFER KH, Akhras S, Himmelsbach K, Hassemer M, et al
    Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level.
    J Hepatol. 2015;62:791-8.
    PubMed     Text format     Abstract available


  217. MATHURIN P, Bataller R
    Trends in the management and burden of alcoholic liver disease.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


  218. ARROYO V, Moreau R, Jalan R, Gines P, et al
    Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


    January 2015
  219. HALFON P, Penaranda G, Ouzan D
    A response-guided approach based on HBsAg kinetics may identify patients with the greatest chance of success.
    J Hepatol. 2015;62:238.
    PubMed     Text format    


  220. NEGRO F
    Are statins a remedy for all seasons?
    J Hepatol. 2015;62:8-10.
    PubMed     Text format    


    December 2014
  221. SOHN W, Paik YH, Cho JY, Lim HY, et al
    Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
    J Hepatol. 2014 Dec 13. pii: S0168-8278(14)00927.
    PubMed     Text format     Abstract available


    November 2014
  222. GAMBATO M, Lens S, Navasa M, Forns X, et al
    Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
    J Hepatol. 2014;61.
    PubMed     Text format     Abstract available


    September 2014
  223. SHOUVAL D, Friedman SL
    Focusing on the Past, Present and Future of Hepatology.
    J Hepatol. 2014 Sep 4. pii: S0168-8278(14)00627.
    PubMed     Text format    


    July 2014
  224. HUANG Y, de Boer WB, Adams LA, MacQuillan G, et al
    Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome.
    J Hepatol. 2014;61:22-7.
    PubMed     Text format     Abstract available


  225. CHIAVAROLI L, Ha V, Kendall CW, Sievenpiper JL, et al
    Is industrial fructose just a marker of an unhealthy dietary pattern?
    J Hepatol. 2014;61:172-3.
    PubMed     Text format    


  226. PETTA S, Marchesini G, Craxi A
    Reply to: "is industrial fructose just a marker of an unhealthy dietary pattern?".
    J Hepatol. 2014;61:173-5.
    PubMed     Text format    


    June 2014
  227. NISCHALKE HD, Lutz P, Kramer B, Sohne J, et al
    A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease.
    J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00401.
    PubMed     Text format     Abstract available


    May 2014
  228. NI HM, Woolbright BL, Williams J, Copple B, et al
    Nrf2 Promotes the Development of Fibrosis and Tumorigenesis in Mice with Defective Hepatic Autophagy.
    J Hepatol. 2014 May 7. pii: S0168-8278(14)00306.
    PubMed     Text format     Abstract available


  229. ROMERO-GOMEZ M, Berenguer M, Molina E, Calleja JL, et al
    Reply to: "Renal impairment and anemia during triple therapy".
    J Hepatol. 2014;60:1100-1.
    PubMed     Text format    


  230. VESPASIANI-GENTILUCCI U, Gallo P, Picardi A
    Renal impairment and anemia during triple therapy.
    J Hepatol. 2014;60:1099-100.
    PubMed     Text format    


    April 2014
  231. EDER E, Scherzer TM, Hofer H, Ferenci P, et al
    Reply to: "DHEA and progesterone have a protective effect on ribavirin-induced hemolysis".
    J Hepatol. 2014;60:898-9.
    PubMed     Text format    


  232. BROCHOT E, Bodeau S, Nguyen-Khac E, Duverlie G, et al
    DHEA and progesterone have a protective effect on ribavirin-induced hemolysis.
    J Hepatol. 2014;60:897-8.
    PubMed     Text format    


  233. HEZODE C, Fontaine H, Barthe Y, Carrat F, et al
    Reply to: "From the CUPIC study: great times are not coming(?)".
    J Hepatol. 2014;60:900-1.
    PubMed     Text format    


  234. SCHMIDT-MARTIN D, Houlihan D, McCormick A
    From the CUPIC study: great times are not coming(?).
    J Hepatol. 2014;60:899-900.
    PubMed     Text format    


  235. SAMAIN A, Duval-Modeste AB, Joly P, Leblanc C, et al
    First case of drug rash eosinophilia and systemic symptoms due to boceprevir.
    J Hepatol. 2014;60:891-3.
    PubMed     Text format     Abstract available


    March 2014
  236. KULIK L, Vouche M, Koppe S, Lewandowski RJ, et al
    Prospective Randomized Pilot Study of Y90 +/- Sorafenib as Bridge to Transplantation in Hepatocellular Carcinoma.
    J Hepatol. 2014 Mar 26. pii: S0168-8278(14)00204.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: